Homepage > Company > Media > Pharma News > 2018 > Former Gilead Sciences R&D chief Norbert Bischofberger named CEO of Kronos Bio

Former Gilead Sciences R&D chief Norbert Bischofberger named CEO of Kronos Bio

Kronos Bio on Wednesday announced the appointment of former Gilead Sciences head of R&D Norbert Bischofberger as its CEO.

The news comes after Bischofberger disclosed in March his intention to leave the drugmaker at the end of last month, having joined the company in 1990.

Bischofberger remarked "the science behind Kronos is compelling," with the company currently advancing two preclinical programmes targeting MYC and the androgen receptor for the treatment of cancer.

May 23rd, 2018

https://www.firstwordpharma.com/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...